• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COPD 患者的纵向评估:多维变异性和结局。

Longitudinal assessment in COPD patients: multidimensional variability and outcomes.

机构信息

Hospital Universitario La Candelaria, Tenerife.

出版信息

Eur Respir J. 2014 Mar;43(3):745-53. doi: 10.1183/09031936.00096913. Epub 2013 Sep 26.

DOI:10.1183/09031936.00096913
PMID:24072210
Abstract

The value and timing of multidimensional assessments in chronic obstructive pulmonary disease (COPD) remains unclear because there is little information about their variability and relationship to outcome. The aim of this study was to determine the progression of COPD using clinical and spirometric variability over time with mortality as the outcome. We determined the annual intra-individual variability of forced expiratory volume in 1 s (FEV1) and BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index in 403 patients with at least five measurements. The pattern was defined as "stable" if the annual change remained constant in ≥66% of the observations and "unstable" if it did not meet that threshold. We explored the minimum number of yearly observations that related to mortality in the 704 patients of the cohort. The "unstable" pattern of FEV1 was seen in 53% and 40% of patients using a threshold of 40 mL·year(-1) and 100 mL·year(-1), respectively. There was a slightly more "stable" pattern in the BODE index (62% for 1 point). A profile associated with mortality was defined by a baseline measurement followed by annual measurements for 2 years of the BODE index, but not its individual components, including FEV1 (p<0.001). Progression of COPD measured using FEV1 is inconsistent and relates poorly to outcome. Monitoring the more stable BODE index better assesses disease progression.

摘要

慢性阻塞性肺疾病(COPD)的多维评估的价值和时机仍不清楚,因为关于其变异性及其与结果的关系的信息很少。本研究的目的是使用临床和肺活量计的时间变化来确定 COPD 的进展,以死亡率为结果。我们确定了至少有 5 次测量值的 403 例患者的 1 秒用力呼气量(FEV1)和 BODE(体重指数、气流阻塞、呼吸困难、运动能力)指数的年度个体内变异性。如果年度变化在≥66%的观察中保持不变,则定义为“稳定”模式,如果不符合该阈值,则定义为“不稳定”模式。我们在队列中的 704 名患者中探索了与死亡率相关的最小年度观察次数。分别使用 40 mL·年(-1)和 100 mL·年(-1)的阈值,53%和 40%的患者出现了 FEV1 的“不稳定”模式。BODE 指数的模式稍为稳定(62%为 1 分)。与死亡率相关的特征是基线测量后,BODE 指数的 2 年的年度测量,但不包括其各个组成部分,包括 FEV1(p<0.001)。使用 FEV1 测量的 COPD 进展不一致,与结果相关性差。监测更稳定的 BODE 指数可更好地评估疾病进展。

相似文献

1
Longitudinal assessment in COPD patients: multidimensional variability and outcomes.COPD 患者的纵向评估:多维变异性和结局。
Eur Respir J. 2014 Mar;43(3):745-53. doi: 10.1183/09031936.00096913. Epub 2013 Sep 26.
2
The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort.慢性阻塞性肺疾病的进展是异质的:BODE 队列的经验。
Am J Respir Crit Care Med. 2011 Nov 1;184(9):1015-21. doi: 10.1164/rccm.201105-0831OC.
3
Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index.肾上腺髓质素通过 BODE 指数改善 COPD 患者的死亡率预测:BODE-A 指数。
Eur Respir J. 2014 Feb;43(2):397-408. doi: 10.1183/09031936.00058713. Epub 2013 Jun 21.
4
The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的体重指数、气流受限、呼吸困难及运动能力指数
N Engl J Med. 2004 Mar 4;350(10):1005-12. doi: 10.1056/NEJMoa021322.
5
The modified BODE index: validation with mortality in COPD.改良的BODE指数:慢性阻塞性肺疾病死亡率的验证
Eur Respir J. 2008 Nov;32(5):1269-74. doi: 10.1183/09031936.00138507. Epub 2008 Jun 25.
6
The cross-sectional and longitudinal association of the BODE index with quality of life in patients with chronic obstructive pulmonary disease.BODE 指数与慢性阻塞性肺疾病患者生活质量的横断面和纵向关联。
Chin Med J (Engl). 2009 Dec 20;122(24):2939-44.
7
Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index.慢性阻塞性肺疾病患者预后评估的扩展:更新后的BODE指数和ADO指数。
Lancet. 2009 Aug 29;374(9691):704-11. doi: 10.1016/S0140-6736(09)61301-5.
8
Multicomponent indices to predict survival in COPD: the COCOMICS study.多组分指数预测 COPD 患者生存:COCOMICS 研究。
Eur Respir J. 2013 Aug;42(2):323-32. doi: 10.1183/09031936.00121012. Epub 2012 Dec 6.
9
Disease progression in young patients with COPD: rethinking the Fletcher and Peto model.COPD 年轻患者的疾病进展:重新思考 Fletcher 和 Peto 模型。
Eur Respir J. 2014 Aug;44(2):324-31. doi: 10.1183/09031936.00208613. Epub 2014 Apr 2.
10
Sex differences in mortality in patients with COPD.慢性阻塞性肺疾病患者死亡率的性别差异。
Eur Respir J. 2009 Mar;33(3):528-35. doi: 10.1183/09031936.00096108. Epub 2008 Dec 1.

引用本文的文献

1
All-cause and cause-specific mortality in individuals with COPD in China: a 16-year follow-up cohort study.中国慢性阻塞性肺疾病患者的全因死亡率和特定病因死亡率:一项16年随访队列研究。
Eur J Epidemiol. 2025 Jun 4. doi: 10.1007/s10654-025-01252-7.
2
From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.从慢阻肺前期到慢阻肺:一个简单、低成本且易于实施的(SLIM)风险计算器。
Eur Respir J. 2023 Sep 28;62(3). doi: 10.1183/13993003.00806-2023. Print 2023 Sep.
3
COPD profiles and treatable traits using minimal resources: identification, decision tree and stability over time.
使用最少资源识别 COPD 表型和可治疗特征:决策树和随时间的稳定性。
Respir Res. 2022 Feb 14;23(1):30. doi: 10.1186/s12931-022-01954-6.
4
[Comparison of different evaluation systems for assessing disease severity and treatment efficacy in patients with chronic obstructive pulmonary disease].[慢性阻塞性肺疾病患者疾病严重程度及治疗疗效评估的不同评估系统比较]
Nan Fang Yi Ke Da Xue Xue Bao. 2021 Jul 20;41(7):1119-1124. doi: 10.12122/j.issn.1673-4254.2021.07.23.
5
When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.COPD 初始三联治疗的时机:根据临床重要恶化评估,在 ICS/LABA 中添加 LAMA。
Int J Chron Obstruct Pulmon Dis. 2020 Dec 22;15:3375-3384. doi: 10.2147/COPD.S279482. eCollection 2020.
6
Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.COPD 疾病活动标志物:ECLIPSE 队列 8 年死亡率研究。
Eur Respir J. 2021 Mar 25;57(3). doi: 10.1183/13993003.01339-2020. Print 2021 Mar.
7
Measuring disease activity in COPD: is clinically important deterioration the answer?评估 COPD 疾病活动度:临床重要恶化是答案吗?
Respir Res. 2020 Jun 2;21(1):134. doi: 10.1186/s12931-020-01387-z.
8
Association of Nonobstructive Chronic Bronchitis With Respiratory Health Outcomes in Adults.非阻塞性慢性支气管炎与成人呼吸系统健康结局的关联。
JAMA Intern Med. 2020 May 1;180(5):676-686. doi: 10.1001/jamainternmed.2020.0104.
9
Female reproductive history in relation to chronic obstructive pulmonary disease and lung function in UK biobank: a prospective population-based cohort study.女性生殖史与英国生物库中慢性阻塞性肺疾病和肺功能的关系:一项前瞻性基于人群的队列研究。
BMJ Open. 2019 Oct 28;9(10):e030318. doi: 10.1136/bmjopen-2019-030318.
10
Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities.在 COPD 患者的常规 6 分钟步行距离和氧饱和度下降的预测因素:合并症的影响。
Int J Chron Obstruct Pulmon Dis. 2019 Jul 2;14:1399-1410. doi: 10.2147/COPD.S188412. eCollection 2019.